{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"290.0","upperLimit":"4740.0","value":"1090.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"Median and range of sorafenib steady state concentration for Induction I.","dispersionType":"Full Range","groups":[{"description":"Arm C (Cohort 1) IND II:cytarabine IT; cytarabine IV; daunorubicin hydrochloride IV; etoposide IV; sorafenib tosylate PO INT I:cytarabine IT; AE chemotherapy as Arm A, Intensification II; sorafenib tosylate PO INT II:cytarabine IT; MA chemotherapy as Arm A, Induction II (HR patients); sorafenib tosylate PO.\n\nSCT (HR pts w/ matched family \\[MFD\\] or unrelated donor): fludarabine phosphate IV; busulfan IV; allogeneic SCT; GVHD prophylaxis.\n\nMAINTENANCE:sorafenib tosylate PO\n\nArm C (Cohort 2 and 3) IND I:cytarabine IT; ADE as Arm A, IND I; sorafenib tosylate PO IND II:cytarabine IT; cytarabine IV; daunorubicin hydrochloride IV; etoposide IV; sorafenib tosylate PO INT I:cytarabine IT; AE as Arm A, INT II, \\& sorafenib tosylate PO INT II:cytarabine IT; MA as Arm A, IND II (HR patients); sorafenib tosylate PO. SCT (HR pts w/ matched family \\[MFD\\] or unrelated donor): fludarabine phosphate IV; busulfan IV; allogeneic SCT; GVHD prophylaxis.\n\nMAINTENANCE:sorafenib tosylate PO","id":"OG000","title":"Arm C"}],"paramType":"MEDIAN","populationDescription":"Data reported from Arm C were collected and analyzed regardless of the cohort as pre-specified in the study protocol. Only eligible patients on Arm C with evaluable Sorafenib steady state concentration data during Induction I are reported.","reportingStatus":"POSTED","timeFrame":"Up to 30 days","title":"Sorafenib Steady State Concentration","type":"SECONDARY","unitOfMeasure":"Nanogram/Milliliter"}